Physician profile
Gary Davis
NPI 1659354413
$1,330.41
in general payments reported to CMS, 2019-2025
28 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $209 · 2021: $301 · 2022: $123 · 2023: $69.67 · 2024: $138 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $456.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $329.29 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $158.87 | 2022-2025 | Caldolor |
| Depuy Synthes Sales INC. | $72.82 | 2020-2021 | |
| Bioventus LLC | $70.72 | 2021-2024 | Exogen Ultrasound Bone Healing System |
| Smith+Nephew, INC. | $68.84 | 2019-2022 | |
| Radius Health, INC. | $65.49 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $62.08 | 2025 | |
| Medline Industries LP | $60.62 | 2024-2025 | Medline Industries, INC. |
| Stryker Corporation | $46.48 | 2025 | Reunion |
| Horizon Therapeutics Plc | $45.64 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $36.54 | 2021-2024 | Iovera, Zilretta, Exparel |
| Avanos Medical | $34.95 | 2023 | Genvisc 850 Sodium Hyaluronate, Trivisc Sodium Hyaluronate |
| Ethicon US, LLC | $30.93 | 2019-2022 | |
| Heron Therapeutics, INC. | $27.02 | 2024-2025 | Zynrelef |
| Organogenesis INC. | $24.08 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $21.98 | 2025 | |
| Sanofi-Aventis U.S. LLC | $21.80 | 2019 | |
| Zimmer Biomet Holdings, INC. | $18.97 | 2019 | |
| Theragen, INC. | $17.25 | 2021 | |
| Boston Scientific Corporation | $16.92 | 2021 | |
| Omnilife Science, INC | $16.28 | 2022 | |
| Endo Pharmaceuticals INC. | $15.56 | 2021 | |
| Zyla Life Sciences, INC. | $14.84 | 2019 | |
| Sanara Medtech INC. | $14.11 | 2020 | |
| Kci USA, INC. | $14.03 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.80 | 2022 | |
| Stimwave Technologies Incorporated | $11.06 | 2022 | |
| Aroa Biosurgery Incorporated | $1.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.